Photo by nci from unsplash
9585Background: The immune checkpoint inhibitors (CI) anti-CTLA-4 (ipilimumab [IPI]) and anti-PD-1 (pembrolizumab [PEM] and nivolumab [NIVO]) have improved survival in advanced melanoma patients (p... Click to show full abstract
9585Background: The immune checkpoint inhibitors (CI) anti-CTLA-4 (ipilimumab [IPI]) and anti-PD-1 (pembrolizumab [PEM] and nivolumab [NIVO]) have improved survival in advanced melanoma patients (p...
Keywords:
anti ctla;
advanced melanoma;
gene profiling;
profiling pretreatment;
immune gene;
melanoma patients
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!